Pacific Biosciences (PACB) shareholders approve 16M-share equity plan increase and 2026 auditor
Rhea-AI Filing Summary
Pacific Biosciences of California, Inc. reported results of its annual stockholder meeting and approval of an equity plan change. Stockholders approved an amendment to the 2020 Equity Incentive Plan, adding 16,000,000 shares of common stock reserved for future equity awards, following prior Board approval.
At the June 3, 2026 meeting, holders of 203,009,375 shares, about 65% of the 310,487,099 shares outstanding as of April 6, 2026, were represented. Stockholders elected Class III directors, ratified Ernst & Young LLP as auditor for 2026, approved named executive officer compensation on an advisory basis, and confirmed the equity plan amendment.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Additional equity plan shares: 16,000,000 shares
Shares outstanding: 310,487,099 shares
Shares represented at meeting: 203,009,375 shares
+4 more
7 metrics
Additional equity plan shares
16,000,000 shares
Increase in shares reserved under 2020 Equity Incentive Plan
Shares outstanding
310,487,099 shares
Common stock outstanding as of April 6, 2026 record date
Shares represented at meeting
203,009,375 shares
Shares present or by proxy at June 3, 2026 annual meeting
Meeting turnout
65%
Approximate percentage of shares entitled to vote represented
Say-on-pay for votes
114,050,930 votes
Votes in favor of named executive officer compensation
Auditor ratification for votes
198,046,666 votes
Votes in favor of Ernst & Young LLP as 2026 auditor
Equity plan amendment for votes
114,865,820 votes
Votes in favor of 2020 Equity Incentive Plan amendment
Key Terms
2020 Equity Incentive Plan, independent registered public accounting firm, non-binding advisory basis, broker non-votes, +1 more
5 terms
2020 Equity Incentive Plan financial
"approved an amendment to the Company’s 2020 Equity Incentive Plan (the “2020 Plan”)"
independent registered public accounting firm financial
"ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding advisory basis financial
"The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers."
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
broker non-votes financial
"For 114,050,930 | Against 21,239,989 | Abstain 1,940,145 | Broker Non-Votes 65,778,311"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
record date financial
"shares of the Company’s common stock outstanding as of 5:00 p.m. (Pacific time) on April 6, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Pacific Biosciences (PACB) stockholders approve at the 2026 annual meeting?
Stockholders approved several items, including an amendment to the 2020 Equity Incentive Plan adding 16,000,000 reserved shares. They also elected Class III directors, ratified Ernst & Young LLP as auditor for 2026, and approved executive compensation on a non-binding advisory basis.
Did PACB stockholders approve executive compensation in 2026?
Yes. Stockholders approved, on a non-binding advisory basis, the compensation of Pacific Biosciences’ named executive officers. The advisory vote received 114,050,930 votes for, 21,239,989 against, and 1,940,145 abstentions, with 65,778,311 broker non-votes recorded.
Which auditor did Pacific Biosciences (PACB) stockholders ratify for fiscal 2026?
Stockholders ratified Ernst & Young LLP as Pacific Biosciences’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 198,046,666 votes for, 3,990,483 against, and 972,226 abstentions, with no broker non-votes.
Were PACB’s Class III directors re-elected at the 2026 annual meeting?
Yes. All nominated Class III directors were elected to serve until the 2027 annual meeting. Each nominee, including William Ericson, Kathy Ordoñez, Christopher M. Smith, Chris Gibson, Christian O. Henry, and John F. Milligan, Ph.D., received more votes for than against.